Title:
BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
Document Type and Number:
WIPO Patent Application WO/2014/151006
Kind Code:
A3
Abstract:
Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
Inventors:
CHEN DANIEL SHIN-YU (US)
HEGDE PRITI (US)
KOEPPEN HARTMUT (US)
KOWANETZ MARCIN (US)
HEGDE PRITI (US)
KOEPPEN HARTMUT (US)
KOWANETZ MARCIN (US)
Application Number:
PCT/US2014/024746
Publication Date:
November 27, 2014
Filing Date:
March 12, 2014
Export Citation:
Assignee:
GENENTECH INC (US)
HOFFMANN LA ROCHE (CH)
HOFFMANN LA ROCHE (CH)
International Classes:
G01N33/574
Foreign References:
| AU2012211347A1 | 2012-08-23 |
Other References:
M. SZNOL ET AL: "Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer", CLINICAL CANCER RESEARCH, vol. 19, no. 5, 1 March 2013 (2013-03-01), pages 1021 - 1034, XP055123957, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2063
SUZANNE L TOPALIAN ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, 28 June 2012 (2012-06-28), United States, pages 2443 - 2454, XP055098235, Retrieved from the Internet [retrieved on 201406], DOI: 10.1056/NEJMoa1200690
D. S. CHEN ET AL: "Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1", CLINICAL CANCER RESEARCH, vol. 18, no. 24, 19 October 2012 (2012-10-19), pages 6580 - 6587, XP055124329, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-1362
HAMID OMID ET AL: "Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.", EXPERT OPINION ON BIOLOGICAL THERAPY JUN 2013, vol. 13, no. 6, 19 February 2013 (2013-02-19), pages 847 - 861, XP008170016, ISSN: 1744-7682
SUZANNE L TOPALIAN ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, 28 June 2012 (2012-06-28), United States, pages 2443 - 2454, XP055098235, Retrieved from the Internet
D. S. CHEN ET AL: "Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1", CLINICAL CANCER RESEARCH, vol. 18, no. 24, 19 October 2012 (2012-10-19), pages 6580 - 6587, XP055124329, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-1362
HAMID OMID ET AL: "Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.", EXPERT OPINION ON BIOLOGICAL THERAPY JUN 2013, vol. 13, no. 6, 19 February 2013 (2013-02-19), pages 847 - 861, XP008170016, ISSN: 1744-7682
Attorney, Agent or Firm:
WONG, Connie et al. (Inc.1 DNA Way,Mail Stop 4, South San Francisco California, US)
Download PDF: